Adenocarcinoma of Esophagogastric Junction(AEG)
Conditions
Interventions
Experimental group:Apatinib: 500 mg qd po, take after meals (as much as possible at the same time every day), day6-14
Docetaxel40mg/m2d1+5-FU2000mg/m2civ46h+CF300mg/m2d1
Control group:Docetaxel40mg/m2d1+5-FU2000mg/m2civ46h+CF300mg/m2d1
Sponsors
The First Affiliated Hospital of Nanchang University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Aged 18-70 years;Life expectancy = 3 months; 2. ECOG(Eastern Cooperative Oncology Group)performance status of 0 - 2; 3. The Pathological diagnosis of Adenocarcinoma of Esophagogastric Junction(AEG) 4. Using of CT or MRIPET-CT and other examination tips with 1 non removable factors: Group1: N3 lymphatic metastasis , mainly refers to the sixteenth groups of patients with lymphatic metastasis; Group 2: Extensive or fused D2 lymph nodes; Group 3: highly locally advanced, T4b; Group 4: Hepatic metastases(H1)Less than 5 of total shift range, less than 8cm in diameter; Group 5: Peritoneal metastasis(CY1,P1). 5. Did not receive any early treatment (radiotherapy, chemotherapy, targeted therapy, immunotherapy, etc.) 6. During the baseline period, hemodynamic indexes (including cytometry, liver and kidney function) are normal. Such as WBC >4.0×10^9/L, neutrophil>1.5×10^9/L, platelet >100×10^9/L, total bilirubin<1.5×ULN, aspartate aminotransferase and alanine aminotransferase<1.5×ULNserum creatinine<1.2mg/dl; 7. During the baseline period, good heart function, no myocardial infarction within six months, no high blood pressure, no kidney disease, and other coronary heart disease can be controlled within the control range. 8. During the baseline period, there are no any other uncontrollable benign diseases, such as lung, kidney, liver, infection and so on; 9. Before and during the treatment, patients havent taken part in Other clinical trials; 10. Signed consent forms voluntarily.
Exclusion criteria
Exclusion criteria: 1. There are lung, brain, bone, and other distal transfer except the liver and the peritoneum; 2. Patients who have willingness to accept Hessaitin's treatment with Her-2 positive; 3. At the same time with other uncontrollable serious diseases : including atrial fibrillation, angina, cardiac insufficiency, ejection fraction less than 50%, uncontrollable hypertension(suffering from hypertension, antihypertensive drugs can not be reduced to the normal range of treatment: systolic blood pressure>140mmHg / diastolic pressure>90mmHg), renal insufficiency; 4. Patients undergoing therapy with other medications (including traditional Chinese Medicine) or can not guarantee to follow the requirements of the study; 5. Drug allergy to this study; 6. Pregnant or lactating women; 7. Women of childbearing age, fertility requirements during the study period.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| R0 Resection Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| DFS;DCR;Chemotherapy Safety;OS of the 1, 3 and 5 year; | — |
Countries
China
Contacts
Public ContactZhigang Jie
The First Affiliated Hospital of Nanchang University
Outcome results
None listed